We are targeting the emerging ATMP (Advanced Therapy Medicinal Products) market with cell products in the regenerative cell replacement segment. We specialize in the GMP-compliant generation of human induced pluripotent stem cells (iPSCs) from allogeneic umbilical cord blood (CB). Our main focus is on setting up an iPSC master cell bank from HLA-homozygous CB units.
HLA (human leukocyte antigen) genes are the major determinant of tissue recognition and rejection in the body. Via combination of parental genes, there are thousands of HLA variants in the population and usually, these are not compatible with one another from an immunological point of view. HLA-homozygous (HLAh) individuals are the very rare exception to this rule.
These aberrant configuration of homozygosity provides immune compatibility with the wider population, which therefore is of great scientific and therapeutic value. We are exploiting this fact by generating iPSCs exclusively from such privileged donors – under conditions that also permit their clinical application in cellular replacement therapies.
The key idea behind is that only a limited number of iPSC lines are needed to prevent immune rejections in a large number of recipient patients. Statistically, each of our GMP-grade HLAh iPSC lines matches the genotypes of thousands up to millions of individuals in the population.
Thus, this master cell bank serves as an “off-the-shelf”- platform for various types of cell therapeutics and has the potential to become the starting material of any future iPSC-based cell therapy in Europe and beyond.
RHEINCELL Therapeutics GmbH, a German Biotech Company, is a new legal entity founded in 2017 based on the ideas and experiences gained at academic institutions and predecessor companies over the last 20 years.
Our interdisciplinary team of scientists and engineers is composed of experts in the areas of iPSC technology, stem cell differentiation, cell banking, medicine and GMP production. RHEINCELL scientists have outstanding expertise in cellular reprogramming and R&D of stem cells at an international level.
JUERGEN WEISSER Chief Executive Officer
Juergen joined RHEINCELL in 2017. He has distinctive knowledge and professional experience in the fields of finance, strategy and M&A. He has previously worked as CEO/CFO in various start-up and mid-sized companies, primarily in the life science industry.
PROFESSOR PETER WERNET Chief Strategic officer
The inception and concept of RHEINCELL was conceived by Peter. His vision was to combine the fields of cord blood cell processing and induced pluripotent stem cells. He was founder and for more than twenty years director of the Institute for Transplantation Diagnostics and Cell Therapeutics (ITZ) at the Heinrich-Heine-University Düsseldorf, home of Europe’s largest allogenic cord blood bank. Moreover, he was Co-Founder and President (1997-2005) of the international NetCord Foundation.
DR. HABIL. BORIS GREBER Chief Scientific Officer
Boris joined RHEINCELL in 2018. Previously, he was independent research group leader at the Max Planck Institute for Molecular Biomedicine. He is an internationally recognized stem cell scientist with an over 10-years track record in basic and applied human iPSC research.
Have a look at our vacant jobs!